

Vitamin C inhibits NO-induced stabilization of HIF-1 α in HUVECs

MARKUS K. MUELLNER¹, SABINE M. SCHREIER¹, BARBARA SCHMIDBAUER¹,
MAGDALENA MOSER¹, PETER QUEHENBERGER², STYLIANOS KAPIOTIS^{2,3},
HANS GOLDENBERG¹ & HILDE LAGGNER¹

¹Center of Pathobiochemistry and Genetics, Department of Medical Chemistry, and ²Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria, and ³The Central Laboratory, Hospital of the Divine Redeemer, Vienna, Austria

(Received date: 19 December 2009; In revised form date: 16 March 2010)

Abstract

HIF-1 α represents the oxygen-regulated sub-unit of the transcription factor HIF-1, which regulates the transcription of numerous genes involved in cellular response to hypoxia and oxidative stress. It is shown here that nitric oxide (NO) induces HIF-1 α stabilization in human endothelial cells from umbilical cords (HUVECs) under normoxic conditions. HIF-1 α protein was increased ~ 36-fold after incubation with 500 μ M DETA-NO, which releases a steady state NO concentration of roughly one thousandth of the initial concentration of the donor. Loading of the cells with vitamin C counteracted NO-induced HIF-1 α accumulation. Based on the observations that oxidative and nitrosative stress can influence the activity of the proteasomal system, which is responsible for the non-lysosomal degradation of proteins, among them HIF-1 α , it was investigated whether NO-induced stabilization of HIF-1 α might be due to reduced 20S proteasomal activity. This hypothesis could not be proved, because NO concentrations to inhibit 20S proteasomal activity were about one order of magnitude higher than that to inhibit HIF-1 α degradation.

Keywords: Nitric oxide, ascorbate, DHA, HIF-1 α , 20S proteasomal activity.

Abbreviations: HIF-1, hypoxia-inducible factor; DHA, dehydroascorbic acid; HUVECs, human umbilical vein endothelial cells; DETA-NO, diethylenetriamine/nitric oxide adduct.

Introduction

Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that induces oxygen-regulated genes in response to reduced oxygen conditions (hypoxia) [1]. The two sub-units of HIF-1, HIF-1 α and HIF-1 β , are constitutively expressed, but HIF-1 α is rapidly degraded by the proteasome system under normoxic conditions and is stabilized during hypoxia. The oxygen content of the cells is sensed by specific prolyl hydroxylases, which hydroxylate HIF-1 α and thus make it a substrate for a ubiquitin ligase [2–6]. The prolyl hydroxylases utilise vitamin C (ascorbate) to keep non-heme iron in the active Fe(II) form. Thus, vitamin C has

been identified as modulator of the hypoxic response [7,8]. It is one of the major antioxidants in the human organism and numerous publications report its putative anti-ageing, healing and anti-carcinogenic properties. Recently, a novel function of ascorbate has gained broad interest in the field of angiology and cardiology and in research on functions of the arterial endothelium. The vitamin protects the blood vessels from the symptoms of endothelial dysfunction, which are a hallmark of arterial diseases, such as arteriosclerosis, coronary artery disease, chronic heart failure, diabetes mellitus and others [9–14]. The mechanisms involved are not resolved so far.

Correspondence: Hilde Laggner, PhD, Center of Pathobiochemistry and Genetics, Department of Medical Chemistry, Medical University of Vienna, Waehringer Strasse 10, 1090 Vienna, Austria. Tel: +43-1-4277-60811. Fax: +43-1-4277-60881. Email: hildegard.laggner@meduniwien.ac.at

However, patients suffering from one of the diseases associated with endothelial dysfunction often have lowered concentrations of ascorbate in plasma, which normally is $\sim 50 \mu\text{M}$. This may be a consequence of enhanced consumption resulting from compensation of increased oxidative stress. Other aspects apart from direct antioxidative effects of ascorbate should be considered in this context: (i) ascorbate was described as a co-factor of the endothelial form of NO-synthase (eNOS), more specifically as a stabilizer of its coenzyme tetrahydrobiopterin [15,16]; (ii) ascorbate can reduce nitrosothiols and nitrite which recently have been suggested to play an important role in regulating the arterial blood flow [17–21]; (iii) ascorbate deficiency may be analogous to hypoxia with respect to the prolyl hydroxylase activity and may thus alter the effect of NO. Although the exact relations are by no means clear, it is established that NO interferes with HIF-1 α expression and that this response depends on the degree of oxygen supply [22–27].

In the present study, we show that NO-induced HIF-1 α stabilization under normoxic conditions is reversed by loading human endothelial cells from umbilical cords (HUVECs) with vitamin C.

It has been assumed that high concentrations of NO can cause nitro-oxidative stress and reactive nitrogen species are known for post-translational protein modification [28]. The proteasome system is responsible for the non-lysosomal degradation of proteins. However, modified, cross-linked and aggregated proteins can act as irreversible inhibitors of the 20S proteasome [29]. Furthermore, it has been reported that NO directly interferes with 20S proteasomal activity and subsequently can block proteasome-mediated protein degradation [30].

Based on these findings, we investigated whether NO-induced HIF-1 α stabilization might be due to inhibition of the 20S proteasome.

Materials and methods

Standard laboratory chemicals were obtained from Sigma (Deisenhofen, Germany), Merck (Darmstadt, Germany) or Fluka (Buchs, Switzerland) if not stated otherwise.

N-Succinyl-Leu-Leu-Val-Tyr7-Amido-4-Methylcoumarin (S-LLVY-AMC) was dissolved in dimethylsulphoxide (2 mM), kept at -20°C and was freshly diluted in buffer prior to use.

Cell culture

Human umbilical vein endothelial cells (HUVECs) were obtained by collagenase digestion of umbilical veins and grown in endothelial cell basal medium (EBM, PromoCell, Heidelberg, Germany) supplemented with 20% (v/v) foetal calf serum (Gibco,

NY), 2 mM glutamine, 50 U/ml streptomycin and 0.1 mg/ml penicillin (PAA-Laboratories, Linz, Austria) and 50 ng/ml endothelial cell growth supplement (BD Biosciences, Schwechat, Austria). Cell viability was determined with trypan blue exclusion or the electronic cell counter CASY Model TTC (Schärfe System, Reutlingen, Germany).

Uptake of vitamin C

HUVECs were grown in fibronectin-pre-coated 6-well plates and washed twice with pre-warmed incubation buffer (TBSG; 140 mM NaCl, 20 mM Tris, 5 mM glucose, pH 7.4). All additions used for the specific experiments were included in a volume of 2 ml and the experiment was started by the addition of ascorbate. Dehydroascorbic acid (DHA) was generated by the conversion of ascorbate to DHA with ascorbate oxidase. Cells were incubated at 37°C and the uptake experiments were stopped at various time points by two washing steps with 1 ml of ice-cold PBS. Then, cells were detached by scraping in PBS, centrifuged at 1000 g for 60 s and re-suspended in 300 μl PBS. For the determination of intracellular vitamin C content, an aliquot of 200 μl was mixed with an equal volume of 10% (w/v) meta-phosphoric acid. The residual suspension was used for determination of protein concentration by Bradford assay. The samples were either analysed immediately by HPLC or frozen at -80°C .

Measurement of ascorbate and DHA by HPLC

Ascorbic acid was assayed by HPLC and electrochemical detection as described previously [31,32]. Conversion of DHA to ascorbate was achieved by addition of 10 mM dithiothreitol in 0.5 M Tris. The reduction was stopped after 10 min with 0.2 M sulphuric acid and DHA concentrations were calculated by subtracting concentrations of ascorbate from those of total ascorbate determined in paired aliquots of the same sample.

Measurement of NO release

The release of NO from DETA-NO was monitored with a nitric oxide sensitive electrode (ISO-NOP, WPI, Berlin, Germany) at 37°C and concentrations were calculated with a calibration curve based upon the chemical reduction of NaNO_2 by KJ and H_2SO_4 according to the manufacturer's protocol.

Induction of HIF-1 α under normoxic conditions and immunoblotting

HUVECs were grown in 6-well plates, loaded with either ascorbate for 24 h or DHA for 30 min, washed twice and increasing concentrations of DETA-NO

were added for 4 h. Cells were washed twice with PBS and lysed in 60 μ l lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1.5 mM MgCl₂, 1 mM EGTA, 100 μ M NaF, 10 μ M Na₃VO₄, 10% (v/v) glycerol, 1% (v/v) NP40, 1% (v/v) protease inhibitor cocktail) for 30 min on ice and sonicated. After centrifugation at 28 000 g for 10 min at 4°C, the protein content in the supernatant was determined by the Bradford assay, proteins were resolved on 8% SDS-polyacrylamide gels and blotted onto nitrocellulose membranes (0.45 μ m; Bio-Rad, Vienna, Austria). Non-specific binding was blocked with 5% milk solution in TBS washing buffer (20 mM Tris-HCl pH 7.4 with 145 mM NaCl, 0.1% (v/v) Tween-20) for 1 h and membranes were incubated with HIF-1 α (BD Biosciences, Schwechat, Austria) and β -actin antibodies in TBS washing buffer containing 3% (w/v) bovine serum albumin (1:250 and 1:2000, respectively) overnight at 4°C. Then, the blots were washed three times for 10 min with washing buffer and incubated with a 1:4000 dilution of goat anti-mouse IgG-horseradish peroxidase-linked antibody (Bio-Rad) diluted in blocking buffer (washing buffer with 5% (w/v) fat-free dry milk) for 1 h. After another washing with TBS, the proteins were revealed using Super Signal Pico (Pierce, Rockford, IL) and a chemiluminescence imager system (ChemiImager 4400 with AlphaEase FC Software, Biozym, Vienna, Austria).

Activity of the 20S proteasome

HUVECs were grown in culture flasks (25 cm²), washed twice with ice-cold PBS, detached by scraping in 100 μ l lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1.5 mM MgCl₂, 10% (v/v) glycerol, 1% (v/v) NP40), transferred into reaction tubes and lysed for 1 h on ice. After centrifugation at 28 000 g at 4°C, the pellets were discarded and supernatants with a protein content of 60 μ g were transferred into reaction tubes with a final volume of 1 ml PBS containing up to 10 mM DETA-NO. Aliquots were transferred into black 96 well plates (Greiner bio-one, Kremsmünster, Austria) and cleavage of AMC from 20 μ M S-LLVY-AMC was monitored by the increase in fluorescence emission at 450 nm with an excitation wavelength set at 355 nm (Wallac, Turku, Finland) over a time period of 100 min at 37°C. Protein concentrations were determined by the Bradford assay.

Measurement of cytotoxicity by neutral red assay

Cells were incubated with the respective compounds, washed twice with PBS and freshly diluted neutral red solution (50 mg/l RPMI 1640-medium) was added [33]. After incubations with the dye for 3 h, cells were washed twice with PBS, lysed in 50% (v/v) ethanol/1% (v/v) acetic acid for 30 min and neutral

red retention was measured in a plate reader at 540 nm (Wallac, Turku, Finland).

Data analysis

All experiments were performed at least three times and the results are presented as means \pm SD. Statistical differences were analysed with GraphPad Prism 3.0 software and comparisons were made by one-way analysis of variance (ANOVA) with *post-hoc* testing using Newman-Keuls' test. A value of $p < 0.05$ was considered significant.

Results

Transport of vitamin C in HUVECs

Vitamin C is accumulated in primary endothelial cells (HUVECs) by two distinct mechanisms: first, there exists a transporter for ascorbate. At a starting concentration of 100 μ M, uptake rates of 26.7 ± 1.4 pmol/min per mg cell protein were measured (Figure 1A). This transporter showed high affinity (K_M 28.3 μ M) and specificity for ascorbate with v_{max} values of 99.8 ± 12.6 pmol/min per mg cell protein (Figure 1B) and was sodium-dependent (Figure 1C). Only 12.5% of intracellular ascorbate was observed with choline instead of sodium in the uptake buffer and a starting concentration of 100 μ M ascorbate. Secondly, when ascorbate was oxidized to dehydroascorbate (DHA), a sodium-independent transporter system mediates uptake. Within the cells, only ascorbate and no DHA was found, indicating that DHA is immediately reduced back to ascorbate. The uptake rates for 100 μ M DHA were 264 ± 65 pmol/min per mg cell protein (Figure 1D) and are ~ 10 -fold higher than the rates observed with ascorbate. The K_M -value was 3.5 mM and v_{max} was 10.7 ± 1.7 nmol/min per mg cell protein (Figure 1E). To test whether DHA transport in these cells was mediated by the facilitative glucose transporters, competition studies were performed using O-methylglucose (3.13–100 mM OMG), a competitive inhibitor of glucose transporters. Uptake of 100 μ M DHA was inhibited half maximal with ~ 10 mM OMG (Figure 1F). In the presence of 10 μ M cytochalasin B, an uncompetitive inhibitor of glucose transporters, $\sim 12\%$ of the original amount of DHA uptake was observed (data not shown). These findings underline that DHA enters HUVEC via glucose transporters.

After verifying that HUVECs transport vitamin C in the oxidized as well as in the reduced form, cells were loaded with either 200 μ M ascorbate for 24 h or with 200 μ M DHA for 30 min. Due to the distinct transport rates both incubations led to an intracellular ascorbate concentration of ~ 2.5 mM, reflecting concentrations found in neutrophils, lymphocytes and monocytes [34]. The actual concentration of ascorbate in endothelial cell *in vivo* is still unknown.




Figure 1. Uptake of ascorbate (A–C) and DHA (D–F) in HUVECs. Time dependence: HUVECs were incubated with 100 μM ascorbate (A) or 100 μM ascorbate together with 3 U/ml ascorbate oxidase to obtain DHA (D) for the indicated times before measurement of the cell content of ascorbate (Asc) by HPLC. Concentration dependence: cells were incubated with up to 400 μM ascorbate (B) or 400 μM ascorbate with 3 U/ml ascorbate oxidase for 20 min (E). Transport specificity: HUVECs were incubated in Tris-buffer with sodium or Tris-buffer with choline and uptake of 100 μM ascorbate was followed for 20 min (C). Transport of 100 μM DHA was followed in the presence of 3.1–100 mM O-methylglucose (F). Results are means ± SD for three experiments, ****p* < 0.001.

Effect of vitamin C on NO-induced HIF-1α protein stabilization

The importance of NO as a signalling molecule with vasorelaxant character in the vascular endothelium is well established. To determine the effect of NO on HIF-1α protein degradation, we used the donor DETA-NO, which releases NO slowly with a constant rate and a half-life of ~ 20 h [35]. By using a sensitive

NO-electrode we quantified steady state NO concentrations of roughly one thousandth of the initial concentrations of DETA-NO.

HIF-1α protein was present in HUVECs at very low amount due to fast degradation by the proteasome complex during normoxic conditions (20% O₂, 5% CO₂) but was accumulated ~ 5.5-fold by 250 μM, ~ 36-fold by 500 μM and ~ 40-fold by 1 mM DETA-NO, respectively (Figures 2A–C).




Figure 2. Effect of vitamin C on NO-induced stabilization of HIF-1 α protein. HUVECs were incubated with either 200 μ M ascorbate for 24 h (A) or 200 μ M DHA for 30 min (B) before increasing concentrations of DETA-NO were added for 4 h. Whole cell extracts were separated by SDS-PAGE and HIF-1 α was detected by Western blot analysis. (C) Combined densitometry of Western blots. Results are means \pm SD for three experiments, *** p < 0.001. Effect of DETA-NO on intracellular ascorbate content (D). HUVECs were loaded with 200 μ M DHA for 30 min and 500 μ M DETA-NO was added for 4 h. Concentrations of intracellular ascorbate were measured by HPLC. Results are means \pm SD for four experiments.

This induction of HIF-1 α protein accumulation was antagonized by pre-incubation of the cells with either 200 μ M ascorbate for 24 h (Figure 2A) or 200 μ M DHA for 30 min (Figure 2B). Irrespective of whether cells were loaded with reduced vitamin C for 24 h or oxidized vitamin C for 30 min, approximately the same intracellular concentrations of ascorbate were measured and very similar inhibitory effects were found and were significant ($p < 0.001$) in the presence of 500 μ M and 1 mM DETA-NO (Figure 2C). Incubation of HUVECs with ascorbate or DHA alone showed no alteration in HIF-1 α protein. To verify that treatment of the cells with DETA-NO does not deplete intracellular ascorbate and hence inhibit HIF-1 α degradation, we loaded HUVECs with 200 μ M DHA for 30 min, incubated them with 500 μ M DETA-NO for 4 h and quantified vitamin C content by HPLC. Figure 2D shows that intracellular ascorbate content was not altered by treatment with the NO donor.

Effect of NO on 20S proteasomal activity

Reactive nitrogen species are known for post-translational protein modification and the 20S proteasome was suggested as a potential target. Therefore, we investigated whether inhibition of functional activity of the 20S proteasome by NO might be involved in reduced HIF-1 α degradation. Cell lysates were incubated with increasing concentrations of DETA-NO and the fluorogenic substrate S-LLVY-AMC at 37°C under light-protected conditions and chymotryptic activity of the 20S proteasome was followed by AMC cleavage in an automated plate reader. The slopes of the time-course data were calculated, and Figure 3 depicts that 20S proteasomal activity was significantly inhibited by 1 mM DETA-NO ($p=0.021$) and was down to 44% with 5 mM DETA-NO compared to untreated controls. Although DETA-NO




Figure 3. Effect of DETA-NO on 20S proteasomal activity. Proteasome was isolated from HUVECs as described in the Methods sections and lysates were incubated with various concentrations of DETA-NO over 100 min at 37°C. Chymotryptic activity of 20S proteasome was followed by AMC cleavage. Results are means \pm SD for four experiments.

at concentrations of 250 μ M and 500 μ M increased HIF-1 α protein significantly, these concentrations were without effect on proteasomal activity.

Ascorbate counteracted the effect of DETA-NO and restored 20S chymotryptic activity from $58.7 \pm 18.1\%$ due to 1 mM DETA-NO to $96.5 \pm 21.3\%$ in the presence of 1 mM DETA-NO together with 1 mM ascorbate (Figure 4).

Influence of high concentrations of NO on cell integrity

The neutral red assay was utilized to investigate the consequences of the incubation with DETA-NO on cell integrity. No changes in cell viability were observed after 4 h treatment of HUVECs with the NO donor at concentrations of up to 10 mM DETA-NO (Figure 5).

Discussion

Vitamin C is one of the major antioxidants in the human body and was suggested to protect the vascular system against endothelial dysfunction [9,11,14]. Cultured endothelial cells from human umbilical cords (HUVECs) accumulated vitamin C in reduced (ascorbate) and oxidized form (DHA). The uptake rates for DHA were \sim 10-fold higher than the rates observed with ascorbate. To estimate the significance of the two modes of vitamin C uptake, one has to consider the concentration ratio of DHA and ascorbate under physiological conditions and the apparent affinities. DHA may not be found at all in human plasma or only at very low concentrations [36]. This means that endothelial cells preferentially acquire ascorbate by uptake of the reduced form. The apparent affinity is 28.3 μ M for HUVECs and within the physiological range of plasma ascorbate, which is between 25–100 μ M [34]. However, whenever ascorbate is oxidized by reaction with




Figure 4. Effect of ascorbate on NO-mediated inhibition of 20S proteasomal activity. Lysates from HUVECs were incubated with 1 mM DETA-NO with or without 1 mM ascorbate for 100 min at 37°C. Results are means \pm SD for three experiments, * $p < 0.05$ vs untreated control.




Figure 5. Effect of DETA-NO on viability of HUVECs. Cells were incubated with up to 10 mM DETA-NO for 4 h and cell integrity was monitored by the neutral red assay. Results are means \pm SD for three experiments.

oxidants, endothelial cells accumulate the oxidized vitamin and recycling of ascorbate from DHA accounts for prevention of irreversible loss. Considering a cell water content of 4 μ l/mg protein for microvascular cells [37] and an intracellular amount of 10 nmol ascorbate/mg protein after incubation with either 200 μ M ascorbate for 24 h or 200 μ M DHA for 30 min, HUVECs accumulated ascorbate at concentrations \sim 2.5 mM. According to the transport of vitamin C into HUVECs, our data are consistent with previous findings [8,38].

Knowles et al. [7] first reported that ascorbate is involved in the hypoxic response by the transcription factor HIF-1 in cancer cells. When we used HUVECs, basal HIF-1 α was present at a very low amount during normoxic conditions (20% O₂) due to fast degradation by the proteasome system. However, treatment of the cells with the NO donor DETA-NO inhibited HIF-1 α degradation. We used up to 1 mM DETA-NO and found that NO was roughly a thousandth of the initial concentration of the releasing compound, reflecting steady state levels of NO that activated platelets can produce locally [39]. NO increased HIF-1 α protein levels dependent on its concentration and was \sim 40-fold following incubations with 1 mM DETA-NO. From these data one might presume that massive NO generated during inflammatory conditions can induce HIF-1 α signalling and upregulation of HIF-1 α responsive target genes may lead to short-time adaptations such as enhanced glycolysis to meet an increased energy demand.

Highly significant reduction of NO-induced HIF-1 α protein accumulation was found by loading HUVECs with vitamin C. It is well established that ascorbate rather preserves NO than it reacts with it. However, one may speculate that reactive products of NO, like the potent oxidant peroxynitrite, generated from NO and superoxide released by endothelial cells, might be responsible for HIF-1 α stabilization and that ascorbate diminishes HIF-1 α by scavenging reactive NO derivatives. Although intracellular ascorbate content

was not altered during incubation with DETA-NO, the changes in intracellular oxidation status could be rather small or ascorbate could be recovered by other antioxidants. Therefore, we can not fully exclude that vitamin C-mediated HIF-1 α reduction was not solely due to its radical scavenging properties.

Several authors have suggested that NO and NO-derived reactive species are involved in post-translational protein modification and cross-linked and aggregated proteins can bind to the 20S proteasome and act as irreversible inhibitors [28,29,30]. Although the 20S proteasome is non-ATP-dependent and more resistant to oxidative stress than the ATP- and ubiquitin-dependent 26S proteasome [40,41], it seems to be the 20S proteasomal core with its chymotrypsin-like activity that is crucial for removing nitrated proteins in plasma [42]. Therefore, we hypothesized that NO-mediated stabilization of HIF-1 α might occur through interaction of NO with the 20S proteasome. Even though this work documents inhibition of the 20S proteasomal activity by high but physiologically relevant concentrations of NO, we could not prove our hypothesis. NO concentrations about one order of magnitude higher than that for HIF-1 α accumulation were required for inhibition of the 20S proteasomal activity. Based on these findings, we conclude that the suppressive effect of NO on HIF-1 α protein degradation is not due to inhibition of the proteasomal activity.

Metzen et al. [25] have proposed that stabilization of HIF-1 α by NO and ROS occurs through binding to the non-heme iron of prolyl hydroxylases (PHDs) to block their activity and inhibit HIF-1 α ubiquitination. In our study, intracellular ascorbate was \sim 2.5 mM and thus was one order of magnitude higher than the K_m values reported for purified PHD reaction [43]. Therefore, our data might provide further evidence that vitamin C is essential for maintaining iron of PHDs in its active Fe(II) form, hence improving PHD activity and possibly preventing binding of NO. On the other hand, S-nitrosylation of cysteine in the oxygen-dependent degradation (ODD) domain was identified as a key mechanism for NO-mediated HIF-1 α stabilization independent of the PHD pathway [44]. Based on these observations, one might speculate that reductants like ascorbate could convert S-nitrosylated proteins back to the reduced and active forms and this could be one of several effects of ascorbate on HIF-1 α degradation. Even though, we are aware that atmospheric oxygen levels (20 % O₂) in cell culture incubators do not exactly reflect in vivo oxygen tension, which has been reported to range between 10 and 13 % in human blood [45], our findings underline the role of vitamin C as a relevant modulator of NO-mediated signalling in the vascular endothelium. However, further studies are necessary to elucidate the underlying mechanisms by which intracellular ascorbate actually prevents NO-induced HIF-1 α accumulation.

Declaration of interest: Markus K. Muellner was supported by the Kamillo Eisner-Stiftung. Sabine M. Schreier was supported by the OeNB Jubiläumsfonds (10537). The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References

- [1] Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. *J Biol Chem* 1993;268:21513–21518.
- [2] Bruck RK, McKnight SL. Oxygen sensing gets a second wind. *Science* 2002;295:807–808.
- [3] Bruck RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. *Science* 2001;294:1337–1340.
- [4] Schofield CJ, Ratcliffe PJ. Signalling hypoxia by HIF hydroxylases. *Biochem Biophys Res Commun* 2005;338:617–626.
- [5] Cioffi CL, Qin Liu X, Kosinski PA, Garay M, Bowen BR. Differential regulation of HIF-1[alpha] prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells. *Biochem Biophys Res Commun* 2003;303:947–953.
- [6] Semenza, GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. *Trends Mol Med* 2001;7:345–350.
- [7] Knowles HJ, Raval RR, Harris AL, Ratcliffe PJ. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. *Cancer Res* 2003;63:1764–1768.
- [8] Vissers MCM, Gunningham SP, Morrison MJ, Dachs GU, Currie MJ. Modulation of hypoxia-inducible factor-1 alpha in cultured primary cells by intracellular ascorbate. *Free Radic Biol Med* 2007;42:765.
- [9] Solzbach U, Hornig B, Jeserich M, Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. *Circulation* 1997;96:1513–1519.
- [10] Duffy SJ, Gokce N, Holbrook M, Hunter LM, Biegelsen ES, Huang A, Keaney JF Jr, Vita JA. Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension. *Am J Physiol Heart Circ Physiol* 2001;280:H528–H534.
- [11] Gokce N, Keaney JF Jr, Frei B, Holbrook M, Olesiak M, Zachariah BJ, Leeuwenburgh C, Heinecke JW, Vita JA. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. *Circulation* 1999;99:3234–3240.
- [12] Sherman DL, Keaney JF Jr, Biegelsen ES, Duffy SJ, Coffman JD, Vita JA. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. *Hypertension* 2000;35:936–941.
- [13] Hernández-Guerra M, García-Pagán JC, Turnes J, Bellot P, Deulofeu R, Abalde JG, Bosch J. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. *Hepatology* 2006;43:485–491.
- [14] Anderson RA, Evans LM, Ellis GR, Khan N, Morris K, Jackson SK, Rees A, Lewis MJ, Frenneaux MP. Prolonged deterioration of endothelial dysfunction in response to postprandial lipaemia is attenuated by vitamin C in Type2 diabetes. *Diabetic Med* 2006;23:258–264.
- [15] Huang A, Vita JA, Venema RC, Keaney JF Jr. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. *J Biol Chem* 2000;275:17399–17406.
- [16] Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. *J Biol Chem* 2001;276:40–47.
- [17] Kim-Shapiro DB, Schechter AN, Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. *Arterioscler Thromb Vasc Biol* 2006;26:697–705.
- [18] Kasuno K, Takabuchi S, Fukuda K, Kizaka-Kondoh S, Yodoi J, Adachi T, Semenza GL, Hirota K. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. *J Biol Chem* 2004;279:2550–2558.
- [19] Crawford JH, Isbell TS, Huang Z, Shiva S, Chacko BK, Schechter AN, Darley-Usmar VM, Kerby JD, Lang JD Jr, Kraus D, Ho C, Gladwin MT, Patel RP. Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. *Blood* 2006;107:566–574.
- [20] Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P, Balzer J, Zotz RB, Scharf RE, Willers R, Schechter AN, Feelisch M, Kelm M. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. *Free Radic Biol Med* 2006;40:295–302.
- [21] Dalsgaard T, Simonsen U, Fago A. Nitrite-dependent vasodilation is facilitated by hypoxia and is independent of known NO-generating nitrite reductase activities. *Am J Physiol Heart Circ Physiol* 2007;292:H3072–H3078.
- [22] Agani FH, Puchowicz M, Chavez JC, Pichiule P, LaManna J. Role of nitric oxide in the regulation of HIF-1alpha expression during hypoxia. *Am J Physiol Cell Physiol* 2002;283:C178–C186.
- [23] Natarajan R, Fisher BJ, Fowler AA. Regulation of hypoxia inducible factor-1 by nitric oxide in contrast to hypoxia in microvascular endothelium. *FEBS Lett* 2003;549:99–104.
- [24] Brune B, Zhou J. The role of nitric oxide (NO) in stability regulation of hypoxia inducible factor-1alpha (HIF-1alpha). *Curr Med Chem* 2003;10:845–855.
- [25] Metzen E, Zhou J, Jelkmann W, Fandrey J, Brune B. Nitric oxide impairs normoxic degradation of HIF-1{alpha} by inhibition of prolyl hydroxylases. *Mol Biol Cell* 2003;14:3470–3481.
- [26] Palmer LA, Gaston B, Johns RA. Normoxic stabilization of hypoxia-inducible factor-1 expression and activity: redox-dependent effect of nitrogen oxides. *Mol Pharmacol* 2000;58:1197–1203.
- [27] Sumbayev VV, Budde A, Zhou J, Brune B. HIF-1[alpha] protein as a target for S-nitrosation. *FEBS Lett* 2003;535:106–112.
- [28] May JM, Qu Z-C. Nitric oxide-induced oxidant stress in endothelial cells: amelioration by ascorbic acid. *Arch Biochem Biophys* 2004;429:106–113.
- [29] Davies KJA. Degradation of oxidized proteins by the 20S proteasome. *Biochimie* 2001;83:301–310.
- [30] Glockzin S, von Knethen A, Scheffner M, Brune B. Activation of the cell death program by nitric oxide involves inhibition of the proteasome. *J Biol Chem* 1999;274:19581–19586.
- [31] Laggner H, Schmid S, Goldenberg H. Hypericin and photodynamic treatment do not interfere with transport of vitamin C during respiratory burst. *Free Radic Res* 2004;38:1073–1081.
- [32] Lykkesfeldt J, Loft S, Poulsen HE. Determination of ascorbic acid and dehydroascorbic acid in plasma by high-performance liquid chromatography with coulometric detection—are they reliable biomarkers of oxidative stress? *Anal Biochem* 1995;229:329.
- [33] Borenfreund E, Puerner J. Toxicity determined in vitro by morphological alterations and neutral red absorption. *Toxicol Lett* 1985;24:119–124.
- [34] Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, Park JB, Lazarev A, Graumlich JF, King J, Cantilena LR. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. *PNAS* 1996;93:3704–3709.

- [35] Kohl R, Zhou J, Brune B. Reactive oxygen species attenuate nitric-oxide-mediated hypoxia-inducible factor-1[alpha] stabilization. *Free Radic Biol Med* 2006;40:1430–1442.
- [36] Dhariwal KR, Hartzell WO, Levine M. Ascorbic acid and dehydroascorbic acid measurements in human plasma and serum. *Am J Clin Nutr* 1991;54:712–716.
- [37] Wilson JX, Dixon SJ, Yu J, Nees S, Tysl K. Ascorbate uptake by microvascular endothelial cells of rat skeletal muscle. *Microcirculation* 1996;2:211–221.
- [38] Ek A, Strom K, Cotgreave IA. The uptake of ascorbic acid into human umbilical vein endothelial cells and its effect on oxidant insult. *Biochem Pharmacol* 1995;50:1339.
- [39] Malinski T, Radomski MW, Taha Z, Moncada S. Direct electrochemical measurement of nitric oxide released from human platelets. *Biochem Biophys Res Commun* 1993;194:960–965.
- [40] Grune T, Reinheckel T, Davies KJA. Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome. *J Biol Chem* 1996;271:15504–15509.
- [41] Jung T, Bader N, Grune T. Oxidized proteins: intracellular distribution and recognition by the proteasome. *Arch Biochem Biophys* 2007;462:231–237.
- [42] Grune T, Klotz L-O, Gieche J, Rudeck M, Sies H. Protein oxidation and proteolysis by the nonradical oxidants singlet oxygen or peroxynitrite. *Free Radic Biol Med* 2001;30:1243–1253.
- [43] Kong X, Alvarez-Castelao B, Lin Z, Castano JG, Caro J. Constitutive/hypoxic degradation of HIF- α proteins by the proteasome is independent of von Hippel Lindau protein ubiquitylation and the transactivation activity of the protein. *J Biol Chem* 2007;282:15498–15505.
- [44] Tschank G, Sanders J, Baringhaus KH, Dallacker F, Kivirikko KI, Günzler V. Structural requirements for the utilization of ascorbate analogues in the prolyl 4-hydroxylase reaction. *Biochem J* 1994;300:75–79.
- [45] Sullivan, M, Galea, P, Latif, S. What is the appropriate oxygen tension for in vitro culture? *Mol Hum Reprod* 2006;12:653.

This paper was first published online on Early Online on 14 April 2010.